Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.

S, Modi; H, Park; RK, Murthy; H, Iwata; K, Tamura; J, Tsurutani; A, Moreno-Aspitia; T, Doi; Y, Sagara; C, Redfern; IE, Krop; C, Lee; Y, Fujisaki; M, Sugihara; L, Zhang; J, Shahidi; S, Takahashi

doi:10.1200/jco.19.02318

Public

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.

Shared by NobleBlocks on Feb 14, 2020 • 12:00 AM UTC

Authors:

Modi S

Park H

Murthy RK

Abstract

<h4>Purpose</h4>Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a topoisomerase I inhibitor payload. A dose escalation and expansion phase I study evaluated the safety and activity of T-DXd in pa...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!